宫颈癌、卵巢癌或子宫内膜癌诊断后保留生育功能治疗及辅助生殖技术使用中的差异
基于加州癌症登记等关联数据的队列研究纳入7736例18-45岁宫颈癌、子宫内膜癌或卵巢癌患者,评估保留生育功能治疗与辅助生殖技术使用的社会人口学差异。宫颈癌保留生育功能手术850例(18.8%)、子宫内膜癌108例(7.2%)、卵巢癌741例(43.3%),辅助生殖技术使用仅52例。结论认为保留生育功能治疗和辅助生殖技术使用存在临床与社会人口学差异。
要点
- 宫颈癌保留生育功能手术850/4521例(18.8%),子宫内膜癌108/1504例(7.2%),卵巢癌741/1711例(43.3%)。
- 辅助生殖技术使用仅52例,与西班牙裔白人种族、18-35岁及私人保险相关。
- 保留生育功能治疗在不同癌症类型中呈现不一致的社会人口学差异模式。
核心结论
- 宫颈癌、子宫内膜癌或卵巢癌病史患者在保留生育功能治疗和辅助生殖技术使用方面存在临床与社会人口学差异。
研究设计与样本
- 基于人群的队列研究,使用加州癌症登记(CCR)、加州全州卫生规划与发展办公室及辅助生殖技术学会的关联数据。
- 纳入2000年1月1日至2015年12月31日诊断为宫颈癌(IA、IB期)、子宫内膜癌(1级、IA、IB期)或卵巢癌(IA、IC期)的18-45岁患者,共7736例。
- 主要结局为接受保留生育功能治疗(保留子宫和至少一个卵巢的手术或药物治疗),次要结局为癌症诊断后辅助生殖技术使用。
- 采用多变量logistic回归估计比值比和95%CI,暴露因素包括诊断年龄、种族和民族、医疗保险、社会经济地位、农村性和产次。
主要发现
- 宫颈癌患者中保留生育功能手术850例(18.8%,n=4521),子宫内膜癌108例(7.2%,n=1504),卵巢癌741例(43.3%,n=1711)。
- 保留生育功能治疗在宫颈癌和卵巢癌幸存者中更常见于年轻患者及种族和民族少数群体。
- 辅助生殖技术使用低(n=52),与西班牙裔白人种族和民族 designation、较年轻年龄(18-35岁)及拥有私人保险相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the presence of sociodemographic and clinical disparities in fertility-sparing treatment and assisted reproductive technology (ART) use among patients with a history of cervical, endometrial, or ovarian cancer. METHODS: We conducted a population-based cohort study of patients aged 18-45 years who were diagnosed with cervical cancer (stage IA, IB), endometrial cancer (grade 1, stage IA, IB), or ovarian cancer (stage IA, IC) between January 1, 2000, and December 31, 2015, using linked data from the CCR (California Cancer Registry), the California Office of Statewide Health Planning and Development, and the Society for Assisted Reproductive Technology. The primary outcome was receipt of fertility-sparing treatment , defined as surgical or medical treatment to preserve the uterus and at least one ovary. The secondary outcome was fertility preservation , defined as ART use after cancer diagnosis. Multivariable logistic regression analysis was used to estimate odds ratios and 95% CIs for the association between fertility-sparing treatment and exposures of interest: age at diagnosis, race and ethnicity, health insurance, socioeconomic status, rurality, and parity. RESULTS: We identified 7,736 patients who were diagnosed with cervical, endometrial, or ovarian cancer with eligible histology. There were 850 (18.8%) fertility-sparing procedures among 4,521 cases of cervical cancer, 108 (7.2%) among 1,504 cases of endometrial cancer, and 741 (43.3%) among 1,711 cases of ovarian cancer. Analyses demonstrated nonuniform patterns of sociodemographic disparities by cancer type for fertility-sparing treatment, and ART. Fertility-sparing treatment was more likely among young patients, overall, and of those in racial and ethnic minority groups among survivors of cervical and ovarian cancer. Use of ART was low (n=52) and was associated with a non-Hispanic White race and ethnicity designation, being of younger age (18-35 years), and having private insurance. CONCLUSION: This study demonstrates that clinical and sociodemographic disparities exist in the receipt of fertility-sparing treatment and ART use among patients with a history of cervical, endometrial, or ovarian cancer.
引用
- Jorgensen K, Meernik C, Wu CF, et al. Disparities in Fertility-Sparing Treatment and Use of Assisted Reproductive Technology After a Diagnosis of Cervical, Ovarian, or Endometrial Cancer. Obstet Gynecol. 2023. PMID: 36649345. doi:10.1097/AOG.0000000000005044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。